通讯作者: 罗炳清, lbqlc@aliyun.com

DOI：10.12201/bmr.202504.00054

Clinical observation of microwave ablation combined with chemotherapy and PD-1 inhibitor for non-small cell lung cancer.

• 摘要：目的:探讨分析微波消融（MWA）联合化疗+PD-1抑制剂治疗非小细胞肺癌( NSCLC)的临床疗效及安全性。方法:收集2021年5月-2022年5月厦门医学院附属第二医院接受微波消融联合化疗+PD-1抑制剂或PD-1抑制剂+化疗的非小细胞肺癌患者的临床资料。根据不同的治疗方案将患者分为联合组与对照组，对照组患者采用PD-1单抗+化疗方案治疗，联合组在对照组PD-1单抗+化疗基础上联合微波消融。对比分析两组患者的治疗有效率（OR）、疾病控制率(DCR)、无进展生存时间(PFS)和不良事件发生率。结果：共收集73例患者，其中联合组40例，对照组33例。联合组的治疗有效率为72.50%，DCR为95.00%，对照组的治疗有效率为54.54%，DCR为81.81%，两组患者治疗有效率及DCR比较，差异均无统计学意义(P=0.111和P=0.073)；联合组患者中位PFS（14.97个月）明显长于对照组（9.87个月），差异具有统计学意义(P＜0.001)；40例患者行微波消融术后均未出现严重不良反应，73例患者行化疗+PD-1抑制剂治疗后不良反应主要为1~2级，2例患者出现3级不良反应。结论：微波消融联合化疗+PD-1抑制剂可延长中晚期NSCLC患者的PFS，且治疗安全性良好。

  关键词： 微波消融；非小细胞肺癌；PD-1抑制剂；无进展生存时间; ; ; 

   

  Abstract: Objective：An exploration and analysis of the clinical efficacy and safety of microwave ablation (MWA) combined with chemotherapy and PD-1 inhibitor for non-small cell lung cancer (NSCLC). Methods：The data of patients with NSCLC who were not suitable for radical surgery or radiotherapy and were histologically confirmed in the Second Affiliated Hospital of Xiamen Medical College from May 2021 to May 2022 were retrospectively collected．The patients receive chemotherapy plus PD-1 inhibitor with or without MWA were included. The include patients were divided into combined group (with MWA) and control group (without MWA) . The overall effective rates, DCR, PFS, and complication rates of the two groups were compared. Results: A total of 73 cases were included. The overall effective rate in the combination therapy group was 72.50%, and the DCR was 95.00%. In the control group, the overall effective rate was 54.54%, and the DCR was 81.81%. There was no statistically significant difference between the two groups in terms of the overall effective rates and DCR(p=0.111and p=0.073, respectively).The PFS of the combined treatment group was 14.97 months, significantly longer than the 9.87 months in the control group(p﹤0.001) .Forty patients who underwent microwave ablation did not experience any severe adverse reactions. Among the 73 patients who received chemotherapy combined with PD-1 inhibitor treatment, the adverse reactions were mainly Grade 1 to Grade 2, with two patients experiencing Grade 3 adverse reactions. Conclusion: MWA combined with chemotherapy plus PD-1 inhibitor can prolong the PFS of patients with NSCLC and has good safety.

  Key words: Microwave ablation; Non-small cell cancer; PD-1 inhibitor; Progression-free survival

  提交时间：2025-04-17

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 郑歆. PD-1免疫诱导治疗在不可切除Ⅲ期NSCLC中的研究进展. 2025. doi: 10.12201/bmr.202501.00025

  乔明旭, 胡伟. 派安普利联合化疗治疗晚期非鳞非小细胞肺癌的疗效分析. 2025. doi: 10.12201/bmr.202508.00045

  刘雪杨, 程柯, 许树才. 非小细胞肺癌患者血液高凝状态治疗研究进展. 2025. doi: 10.12201/bmr.202506.00015

  王子婕, 张鑫众. 叶酸受体阳性循环肿瘤细胞与非小细胞肺癌发生发展的研究进展. 2025. doi: 10.12201/bmr.202506.00024

  付思思. 非小细胞肺癌患者肺叶切除术后恶心呕吐Nomogram分析模型构建与验证. 2025. doi: 10.12201/bmr.202507.00001

  吴稚晖, 刘红, 周晓雨, 张茜, 谭年喜. RUNX3、P16和DAPK基因启动子DNA甲基化与非小细胞肺癌化疗敏感性的关系. 2025. doi: 10.12201/bmr.202510.00045

  王耀强, 汪浩浩, 罗长江. HMGB1在胃癌进展和治疗中的作用. 2024. doi: 10.12201/bmr.202412.00009

  李颖, 王晓妃, 陆圣威, 董丹妮, 张景峰, 郑建军. 免疫检查点抑制剂相关性肺炎CT表现与临床特点分析. 2024. doi: 10.12201/bmr.202407.00008

  王世荣, 党亚龙. ROCK抑制剂降眼压的研究现状及展望. 2022. doi: 10.12201/bmr.202210.00014

  王亚楠, 王欢, 马莹, 田婧楠, 卢义. 免疫检查点抑制剂相关性甲状腺功能减退的中西医诊疗进展. 2025. doi: 10.12201/bmr.202505.00004

• 序号	提交日期	编号	操作
  1	2025-03-01	10.12201/bmr.202504.00054V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论